Celon Pharma SA
WSE:CLN
Intrinsic Value
The intrinsic value of one CLN stock under the Base Case scenario is 8.14 PLN. Compared to the current market price of 24.2 PLN, Celon Pharma SA is Overvalued by 66%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Celon Pharma SA
Fundamental Analysis

Revenue & Expenses Breakdown
Celon Pharma SA
Balance Sheet Decomposition
Celon Pharma SA
Current Assets | 193.3m |
Cash & Short-Term Investments | 103.3m |
Receivables | 55.1m |
Other Current Assets | 34.8m |
Non-Current Assets | 425.9m |
Long-Term Investments | 80.8m |
PP&E | 315.8m |
Intangibles | 10.2m |
Other Non-Current Assets | 19.1m |
Free Cash Flow Analysis
Celon Pharma SA
PLN | |
Free Cash Flow | PLN |
Earnings Waterfall
Celon Pharma SA
Revenue
|
280.8m
PLN
|
Cost of Revenue
|
-64.1m
PLN
|
Gross Profit
|
216.7m
PLN
|
Operating Expenses
|
-194.9m
PLN
|
Operating Income
|
21.9m
PLN
|
Other Expenses
|
-3.4m
PLN
|
Net Income
|
18.5m
PLN
|
CLN Profitability Score
Profitability Due Diligence
Celon Pharma SA's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
Score
Celon Pharma SA's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
CLN Solvency Score
Solvency Due Diligence
Celon Pharma SA's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Score
Celon Pharma SA's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CLN Price Targets Summary
Celon Pharma SA
According to Wall Street analysts, the average 1-year price target for CLN is 27.74 PLN with a low forecast of 15.66 PLN and a high forecast of 40.95 PLN.
Dividends
Current shareholder yield for CLN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one CLN stock under the Base Case scenario is 8.14 PLN.
Compared to the current market price of 24.2 PLN, Celon Pharma SA is Overvalued by 66%.